Mr. Robert Bechard reports
TETRA BIO-PHARMA ANNOUNCES STOCK OPTION GRANTS
Tetra Bio-Pharma Inc. has granted, pursuant to the company's stock option plan, 375,000 options to officers of the company. Each option entitles its holder to purchase one common share of the company.
A total of 300,000 options will become vested in four six-month tranches of 75,000 options, are exercisable at a price of 69 cents and will expire on Dec. 24, 2022. A total of 75,000 options vest immediately, are exercisable for a period of four years at a price of 69 cents and will expire on Feb. 8, 2023. All of the options are subject to the terms of the plan and the requirements of the TSX Venture Exchange.
As approved at the annual meeting of shareholders of the company held on June 19, 2018, the plan allows the company to issue the equivalent of up to 10 per cent of the number of issued and outstanding common shares from time to time. There are currently 166,831,731 issued and outstanding common shares.
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada-approved, and Food and Drug Administration-reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their health care providers. The company has several subsidiaries engaged in the development of an advanced and growing pipeline of biopharmaceuticals, natural health and veterinary products containing cannabis and other medicinal plant-based elements. With patients at the core of what it does, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.